Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age70+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Eligibility criteria
Qualifiers
Patients ≥ 70 years-old
Confirmed advanced or metastatic renal-cell carcinoma
Patients not previously treated in metastatic setting
Performance Status 0 to 2
Disqualifiers
Participation in another clinical study with an investigational product during the last four weeks and while on study treatment (Patients may be included in CABOLD if they are included in the arm B of CARE1 study EUCT N° 2023-503317-29-00)
Performance Status > 2
Any condition that represent a contraindication to Cabozantinib and/or Nivolumab, as described in summaries of products characteristics, including symptomatic untreated brain metastasis or active auto-immune disease requiring systemic immunosuppressant/modulator (thyroid or adrenal disorder are not an exclusion criteria)
Any severe cardiovascular or thrombo-embolic event in the last three months
Trial design
Treatments tested in this trial
- Nivolumab
- Cabozantinib
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Lead sponsor
Ipsen
Collaborator
Source ClinicalTrials.gov